Table 3.
Multivariable logistic regression analyses of clinicopathologic factors associated with BRAF mutation
| BRAF wild-type | BRAF mutation | Odds-ratio (95%CI)# | p-value | |
|---|---|---|---|---|
| European and North American melanomas n=409* | N=201 | N=208 | ||
| Anatomic site of melanoma | ||||
| Face, scalp, upper extremities | 84 | 33 | 1 | |
| Trunk | 76 | 121 | 2.7 (1.5-4.9) | 0.001 |
| Lower Extremities | 41 | 54 | 2.2 (1.1-4.1) | 0.018 |
| Solar elastosis score | ||||
| ≥6 | 100 | 43 | 1 | |
| 0 to 5 | 101 | 165 | 1.8 (1.1-3.1) | 0.024 |
| Age at diagnosis | ||||
| ≤ 60 years | 78 | 140 | 1 | |
| > 60 years | 123 | 68 | 0.4 (0.3-0.7)## | <0.001 |
| Australian melanomas n=118** | N=73 | N=45 | ||
| Anatomic site of melanoma | ||||
| Face and scalp | 46 | 15 | 1 | |
| Trunk | 27 | 30 | 2.8 (1.2-6.6) | 0.014 |
| Solar elastosis score | ||||
| 9 or 10 | 19 | 2 | 1 | |
| 0 to 8 | 54 | 43 | 4.3 (0.91-20.0) | 0.067 |
| Age at diagnosis | ||||
| > 60 years | 46 | 20 | 1 | |
| ≤ 60 years | 27 | 25 | 2.1 (0.91-4.8) | 0.085 |
*
Sample size reduced because of missing values for age and sex
**
sample size reduced because of missing values for age
#
95%-CI = 95% confidence interval; both models were adjusted for the confounding effects of gender.
##
If the >60 years group was used as the reference category, the odds ratio (95%CI) was 2.4 (1.5-3.7).
Note: For the Australian samples, the cutoff used to dichotomize CSD was optimized due to the smaller sample size. For the same cutoff used for the European and Australian samples see Supplementary Table 2.